{"public_id":"co_ff895d7fe7ebf8cd30c4f5798a5dfccb","status":"active","merged_into_public_id":null,"resolved_public_id":"co_ff895d7fe7ebf8cd30c4f5798a5dfccb","name":"leukemic evolution","description":"The progression of MDS to acute leukemia, used as an endpoint in the prognostic model.","aliases":["leukemic evolution probability"],"types":["outcome"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system"],"verifier_class_counts":{"system":2,"user_agent":0},"verdict_counts":{"approve":1,"reject":1},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":36343021,"title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.","citation_count":1023,"url":"https://sah.borca.ai/papers/36343021"}],"claims":[{"public_id":"cl_4fae2d15a5120907806cb11e86663e1b","text":"WPSS predicts survival and leukemia progression at any time during follow-up (P < .001), and its prognostic value was confirmed in a validation cohort of 739 patients.","corpus_id":36343021,"url":"https://sah.borca.ai/claims/cl_4fae2d15a5120907806cb11e86663e1b"},{"public_id":"cl_7d9a165ef88d11b91c8c2987cc2adbcb","text":"The WHO classification-based prognostic scoring system (WPSS) classifies patients into five risk groups showing different survivals (median survival from 12 to 103 months) and probabilities of leukemic evolution (P < .001).","corpus_id":36343021,"url":"https://sah.borca.ai/claims/cl_7d9a165ef88d11b91c8c2987cc2adbcb"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_ff895d7fe7ebf8cd30c4f5798a5dfccb","url":"https://sah.borca.ai/concepts/co_ff895d7fe7ebf8cd30c4f5798a5dfccb"}